AUAUniversity

American Urological Association

The AUAUniversity podcast is an official podcast of the American Urological Association. More information can be found at https://auau.auanet.org

  1. Update Series (2026) Lesson 18: Testosterone Therapy: Is It Safe? A Case-Based Approach

    vor 14 Std.

    Update Series (2026) Lesson 18: Testosterone Therapy: Is It Safe? A Case-Based Approach

    Update Series (2026) Lesson 18: Testosterone Therapy: Is It Safe? A Case-Based Approach Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit cme.auanet.org/URL/US2026

    35 Min.
  2. AUA Guidelines: Advanced Prostate Cancer

    24. Juni

    AUA Guidelines: Advanced Prostate Cancer

    AUA Guidelines: Advanced Prostate Cancer Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Kristen R. Scarpato, MD, MPH To access the full guideline, please use the following link: https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer

    23 Min.
  3. AUA2026: Focus on: Metastatic Urothelial Carcinoma (mUC)

    17. Juni

    AUA2026: Focus on: Metastatic Urothelial Carcinoma (mUC)

    AUA2026: Focus on: Metastatic Urothelial Carcinoma CME Available: https://cme.auanet.org/URL/FOCUS264ONL LEARNING OBJECTIVES: After participating in this CME activity, participants will be able to: 1. Select appropriate first-line therapies for patients with locally advanced or metastatic urothelial carcinoma during initial treatment planning, in accordance with updated NCCN guidelines. 2. Evaluate holistic management approaches, including treatment sequencing, therapy transitions, and long-term follow-up for patients with locally advanced or metastatic urothelial carcinoma throughout the course of disease. 3. Implement strategies to recognize, monitor, and mitigate treatment-related adverse events in patients receiving systemic therapy for locally advanced or metastatic urothelial carcinoma. 4. Integrate shared decision-making tools and communication strategies into clinical practice to ensure alignment of treatment choices with patient values and caregiver input. 5. Distinguish between treatment pathways for different stages of advanced bladder cancer, including variant histologies to ensure accurate staging and appropriate therapy selection based on the latest NCCN guidelines. ACKNOWLEDGEMENTS Support provided by independent educational grants from: Merck & Co., Inc. Pfizer, Inc.

    1 Std. 8 Min.
  4. AUA Guidelines: Clinically Localized Prostate Cancer

    10. Juni

    AUA Guidelines: Clinically Localized Prostate Cancer

    AUA Guidelines: Clinically Localized Prostate Cancer Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: James Eastham, MD, FACS To access the full guideline, please use the following link: https://www.auanet.org/guidelines-and-quality/guidelines/clinically-localized-prostate-cancer

    28 Min.
  5. Update Series (2026): Kidney Stones and the Infected Patient

    3. Juni

    Update Series (2026): Kidney Stones and the Infected Patient

    Update Series (2026): Kidney Stones and the Infected Patient Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Mantu Gupta, MD Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit CME.auanet.org

    21 Min.
  6. AUA2026: Focus on: Biomarkers, MRI and PSMA PET Imaging in Prostate Cancer Webcast

    27. Mai

    AUA2026: Focus on: Biomarkers, MRI and PSMA PET Imaging in Prostate Cancer Webcast

    AUA2026: Focus on: Biomarkers, MRI and PSMA PET Imaging in Prostate Cancer Webcast CME Available: https://cme.auanet.org/URL/FOCUS262ONL LEARNING OBJECTIVES: After participating in this CME activity, participants will be able to: 1. Critically appraise recent developments in imaging biomarkers and molecular diagnostics (e.g., genomic risk scores, liquid biopsy) and discuss how they complement MRI and PSMA PET in prostate cancer care. 2. Determine the optimal clinical scenarios (diagnostic, staging, recurrence, surveillance) in which PSMA PET/CT or PET/MRI adds value beyond conventional imaging. 3. Recognize potential pitfalls in PSMA PET interpretation — including false positives, false negatives, non–PSMA-expressing disease, and technical artifacts — and implement strategies to mitigate them. 4. Synthesize biomarker, MRI, and PSMA PET findings into a personalized management plan, including guiding biopsy, focal therapy, salvage therapy, or systemic treatments. 5. Select appropriate patients with radiorecurrent or organ-confined prostate cancer for advanced imaging and guide re-treatment decisions (e.g., salvage therapy, targeted radiotherapy). ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Blue Earth Diagnostics, Inc. Lantheus Medical Imaging

    1 Std. 16 Min.
  7. AUA2026 Spotlight: PARP-Inhibitor Combination Treatments for the Urologic Care Team

    20. Mai

    AUA2026 Spotlight: PARP-Inhibitor Combination Treatments for the Urologic Care Team

    AUA2026 Spotlight: PARP-Inhibitor Combination Treatments for the Urologic Care Team CME Available: https://cme.auanet.org/URL/PARP26ONL LEARNING OBJECTIVES: At the conclusion of this CME activity, participants will be able to: 1. Integrate biomarker and genetic testing principles into clinical workflows for patients with metastatic prostate cancer, including when to order testing, how to interpret HRR mutation results (inclusive of BRCA and non-BRCA), and how to address barriers to testing through multidisciplinary coordination. 2. Explain the mechanism of action of PARP inhibitors and the biological and clinical rationale for their use—both as monotherapy and in combination approaches—in the treatment of mPC. 3. Evaluate emerging efficacy and safety data on PARPi combinations, including patient subgroup analyses, sequencing strategies, and the role of combination therapy in different stages of mPC. 4. Apply best practices for side effect monitoring and mitigation in patients receiving PARP inhibitors alone or in combination, leveraging the multidisciplinary team for optimal therapy management and patient quality of life. 5. Implement guideline-concordant care strategies in practice, including genetic testing workflow implementation, coordination among care team members, and patient engagement in shared decision-making and clinical trial enrollment. 5. Utilize current evidence-based guidelines to select and sequence PARP inhibitor therapy for patients with mPC, optimizing oncologic outcomes while individualizing care based on molecular profile and patient-specific factors. ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Astrazeneca Merck & Co., Inc Pfizer, Inc.

    46 Min.
  8. Update Series (2026) Lesson 15: Case-Based Testicular Cancer Clinical Practice Guidelines

    13. Mai

    Update Series (2026) Lesson 15: Case-Based Testicular Cancer Clinical Practice Guidelines

    Update Series (2026) Lesson 15: Case-Based Testicular Cancer Clinical Practice Guidelines Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit cme.auanet.org/URL/US2026

    42 Min.
Alle anzeigen (406)

Info

The AUAUniversity podcast is an official podcast of the American Urological Association. More information can be found at https://auau.auanet.org

Informationen

  • Erstellt von
    American Urological Association
  • Jahre aktiv
    2016 - 2026
  • Folgen
    406
  • Bewertung
    Unbedenklich
  • Copyright
    © All rights reserved
  • Sendungswebsite
    AUAUniversity

Das gefällt dir vielleicht auch